Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer

Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment

(2017) Cedar H.A. Boakye et al.   JOURNAL OF CONTROLLED RELEASE

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Ultra-flexible nanocarriers for enhanced topical delivery of a highly lipophilic antioxidative molecule for skin cancer chemoprevention

(2016) Cedar H.A. Boakye et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer

(2016) Ravi Doddapaneni et al.   EXPERIMENTAL CELL RESEARCH

Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer

(2016) Ketan Patel et al.   MOLECULAR PHARMACEUTICS

Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer

(2016) Ketan Patel et al.   Nanomedicine

Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3

(2015) Scott Boyd et al.   JOURNAL OF MEDICINAL CHEMISTRY

Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer

(2015) Ketan Patel et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer

(2015) Nirmala Chandralega Kampan et al.   Biomed Research International

Abstract 962: Identification of a PFKFB3 inhibitor suitable for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib

(2015) Julie O'Neal et al.   CANCER RESEARCH

Modeling cancer glycolysis under hypoglycemia, and the role played by the differential expression of glycolytic isoforms

(2014) Alvaro Marín-Hernández et al.   FEBS Journal

PEG — A versatile conjugating ligand for drugs and drug delivery systems

(2014) Atul Kolate et al.   JOURNAL OF CONTROLLED RELEASE

6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27

(2014) A Yalcin et al.   Cell Death & Disease

p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents

(2013) Xinbing Sui et al.   CANCER LETTERS

Tumor glycolysis as a target for cancer therapy: progress and prospects

(2013) Shanmugasundaram Ganapathy-Kanniappan et al.   Molecular Cancer

Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer

(2013) B. F. Clem et al.   MOLECULAR CANCER THERAPEUTICS

Ascorbic Acid and a Cytostatic Inhibitor of Glycolysis Synergistically Induce Apoptosis in Non-Small Cell Lung Cancer Cells

(2013) Saleha B. Vuyyuri et al.   PLoS One

Caspase Functions in Cell Death and Disease

(2013) D. R. McIlwain et al.   Cold Spring Harbor Perspectives in Biology

Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction

(2011) James D. Orth et al.   MOLECULAR BIOLOGY OF THE CELL

Mechanisms and functions of p38 MAPK signalling

(2010) Ana Cuadrado et al.   BIOCHEMICAL JOURNAL

RNA-Based Gene Therapy for HIV with Lentiviral Vector-Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma

(2010) D. L. DiGiusto et al.   Science Translational Medicine

siRNA vs. shRNA: Similarities and differences

(2009) Donald D. Rao et al.   ADVANCED DRUG DELIVERY REVIEWS

RNA Interference: From Basic Research to Therapeutic Applications

(2009) Jens Kurreck   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

High transfection efficiency and low toxicity cationic lipids with aminoglycerol–diamine conjugate

(2008) Boon-ek Yingyongnarongkul et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Glycolytic enzyme inhibitors in cancer treatment

(2008) Roberto Scatena et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth

(2008) B. Clem et al.   MOLECULAR CANCER THERAPEUTICS